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Metabolic profiling during ex vivo 
machine perfusion of the human 
liver
Bote G. Bruinsma1,2, Gautham V. Sridharan1, Pepijn D. Weeder1,3, James H. Avruch4, 
Nima Saeidi1, Sinan Özer1, Sharon Geerts1, Robert J. Porte3, Michal Heger2, 
Thomas M. van Gulik2, Paulo N. Martins5, James F. Markmann4, Heidi Yeh4 & Korkut Uygun1
As donor organ shortages persist, functional machine perfusion is under investigation to improve 
preservation of the donor liver. The transplantation of donation after circulatory death (DCD) livers 
is limited by poor outcomes, but its application may be expanded by ex vivo repair and assessment 
of the organ before transplantation. Here we employed subnormothermic (21 °C) machine perfusion 
of discarded human livers combined with metabolomics to gain insight into metabolic recovery 
during machine perfusion. Improvements in energetic cofactors and redox shifts were observed, as 
well as reversal of ischemia-induced alterations in selected pathways, including lactate metabolism 
and increased TCA cycle intermediates. We next evaluated whether DCD livers with steatotic and 
severe ischemic injury could be discriminated from ‘transplantable’ DCD livers. Metabolomic profiling 
was able to cluster livers with similar metabolic patterns based on the degree of injury. Moreover, 
perfusion parameters combined with differences in metabolic factors suggest variable mechanisms 
that result in poor energy recovery in injured livers. We conclude that machine perfusion combined with 
metabolomics has significant potential as a clinical instrument for the assessment of preserved livers.
Liver transplantation is currently the only curative treatment option for patients suffering from end-stage liver 
disease. However, transplantation continues to be limited by organ availability. A great number of donor livers 
are deemed unsuitable for transplantation and are discarded. The suitability of organs for transplantation is deter-
mined on the basis of empirically-established clinical parameters that have been shown to result in increased 
rates of early allograft dysfunction or biliary complications. Such clinical parameters, including prolonged warm 
ischemia (> 30 min) during donation after circulatory death (DCD)1 and hepatosteatosis2, are related to an 
increased susceptibility of the organ to ischemia and reperfusion (I/R) injury during liver preservation and trans-
plantation. Alleviation of I/R injury as well as improved viability testing before the transplantation are likely to 
extend the utilization of otherwise suboptimal organs.
To this end, functional ex vivo machine perfusion is gaining clinical interest for the recovery and assessment 
of liver grafts prior to transplantation. A paradigm-shift from metabolic/functional suppression during cold stor-
age to metabolic support in (sub)normothermic liver perfusion potentiates a more active recovery and more 
representative evaluation of the metabolic state before transplantation. Various pre-clinical models have shown 
improved transplant outcome following functional machine perfusion at both normothermic (body temperature; 
± 37 °C) and subnormothermic temperatures (± 21 °C)3,4, maintaining or even improving function in initially 
discarded human grafts5,6. The feasibility of perfusion preservation as an alternative to static cold preservation is 
supported by initial clinical results with hypothermic machine perfusion7,8.
Importantly, ex vivo assessment of organ quality prior to implantation could allow dynamic assessment of 
recovery during perfusion by providing an accurate indication of whether a liver has been sufficiently improved. 
This approach may also replace the currently employed appraisal of liver viability with in-depth profiling of 
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hepatic function on a liver-to-liver basis. Although several ex vivo viability indicators such as bile production9, 
adenosine triphosphate content6, and hepatic aminotransferase release10 are used during functional liver per-
fusion, very little is known about the molecular mechanisms of ex vivo recovery of the liver and the metabolic 
processes that underlie functional recovery.
Innovative metabolomic analysis techniques have enabled the identification of key pathways and mechanisms 
involved in hepatobiliary disease and have revealed biomarkers associated with donor liver function11–13. Since 
metabolomics involves the study of downstream products of multiple physiological and pathological processes, 
it may offer a unique broad-spectrum perspective of the transplant liver – an organ that hosts an unequaled 
plethora of metabolic interactions14. The rapid change in the metabolic conditions of to-be-transplanted livers 
during the perioperative period warrant metabolomic assessment. However, while metabolic recovery plays a 
vital role in clinically successful machine perfusion, the metabolomic signatures of ex vivo perfused livers remain 
underexplored.
To address this, we performed a comprehensive assessment of human livers in a functional subnormothermic 
machine perfusion (SNMP) platform (Fig. 1). Moreover, groups of steatotic DCD livers (warm ischemia time 
(WIT) < 30 min) and livers with severe warm ischemia (> 30 min) were compared to control DCD livers (WIT 
< 30 min), which met transplantation criteria, to assess the potential of metabolic profiling in discriminating 
between various states of injury.
Materials and Methods
Study protocol. Twenty-one human livers were evaluated during 3 hours of SNMP. Livers were procured in 
the New England Organ Bank (NEOB) region, following standard procurement technique for orthotopic trans-
plantation, and were rejected for transplantation by all offered transplant centers and consented for research. 
Livers were donated after circulatory death (DCD; n = 18) or after brain death (DBD; n = 3). To maximally stand-
ardize the experimental approach and reduce confounding variables in human liver donors and the procurement 
surgery, metabolomic analysis was performed on DCD livers that met the following criteria. Nonsteatotic (0% 
macro- and microvesicular) livers that met DCD transplantation criteria (including WIT < 30 min) and were 
discarded for logistical reasons were used as DCD controls (DCD < 30 min group (WIT range 19–23 min); min 
n = 3). Nonsteatotic DCD livers with severe warm ischemia (DCD > 30 min group (WIT range 36–54 min); 
n = 3) and DCD livers discarded with moderate-severe (> 33% macro/micro-) steatosis and WIT of < 30 min 
were analyzed (Steatotic DCD group; (WIT range 16–27 min); n = 3) as groups with severe injury. All livers were 
from donors less than 70 years of age (Table S1).
Wedge liver biopsies (300–500 mg) were taken before, and hourly during SNMP and used for histological-, 
ultrastructural-, metabolomic-, and biochemical analysis. Samples of the perfusate were collected every 30 min 
and were assessed for hepatic injury and function markers. As controls, liver samples (n = 12) were collected 
from patients undergoing bariatric surgery for weight loss indications, where the WIT was kept to a minimum 
(< 5 min). Informed consent was obtained from the patients before surgery. These samples varied in fat content 
from 0–5% (n = 6), 5–66% (n = 4) to > 66% (n = 2), successfully representing the variation in perfused livers. All 
biopsies underwent frozen homogenization.
The Massachusetts General Hospital Institutional Review Board (IRB) and the New England Organ Bank 
(NEOB) approved this study (No. 2011P001496) and all studies were carried out in accordance with IRB and 
NEOB approved guidelines.
Subnormothermic machine perfusion platform. Validation and technical details of the system for 
support of human livers can be found elsewhere6. Briefly, the SNMP system provided oxygenated (95% O2, 5% 
CO2) perfusion of the hepatic portal vein (PV) and artery (HA) with a nutrient-rich, cell-free, and oxygenated 
perfusate. Organ temperature was ambiently maintained at 21 °C.
Figure 1. Schematic representation of the SNMP system. Two parallel circulations provide continuous flow of 
oxygenated perfusate to the liver through the portal vein (left) and hepatic artery (right). Flow and pressure on 
the vessels are monitored continuously. Oxygenation of the perfusate was provided by membrane oxygenators 
using carbogen gas(95% O2/5% CO2) mixture. The temperature is ambiently maintained at 21 ± 0.3 °C. The 
pressure of the system is controlled by flow adjustments to achieve target pressures of 3–7 mmHg and 30–80 
mmHg on the PV and HA, respectively.
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Determination of liver function. Oxygen uptake was calculated from the difference between in- and out-
flow dissolved oxygen content as described elsewhere6. Liver function was determined using the indocyanine 
green (ICG) clearance test. ICG clearance was measured in seven livers at random (indicated in Table S1). At the 
end of perfusion, 10 mg ICG was added to and thoroughly mixed in the organ bowl and left to circulate with the 
perfusate for 3 minutes. Samples were collected every 2 minutes for 25 minutes and a final sample after 30 minutes. 
The concentration of ICG in the perfusate was measured spectrophotometrically at 800 nm.
Biochemical assays. ATP assay. Absolute levels of adenosine triphosphate (ATP) were determined in liver 
biopsies with a luminescence-based assay (Cell Viability Kit; Biovision). Briefly, nucleotides were extracted from 
~1 mg of pulverized tissue and peak luminescence was measured for 60 seconds in a single tube. ATP concentra-
tions were normalized to tissue protein content determined by the BCA protein assay (Thermo Fisher Scientific, 
Waltham, MA).
Alanine transaminase assay.  ALT concentration was determined in the perfusate by assessing the enzymatic 
conversion of L-alanine by ALT and LDH in a kinetic assay (Infinity Reagent; Thermo Fisher Scientific).
Targeted metabolomics – cofactor analysis. Crushed tissue biopsies (~25 mg) from the three afore-
mentioned groups were analyzed for metabolic cofactors (ATP/ADP/AMP, NADH/NAD+, NADPH/NADP, FAD, 
and GSH/GSSG) using targeted multiple reaction monitoring analysis on a 3200 QTRAP LC/MS-MS (Triple 
quadrupole liquid chromatography – mass spectrometry) system (AB Sciex, Foster City, CA). For a more detailed 
description of the methodology readers are referred to the supplementary methods.
Untargeted metabolomics analysis. Untargeted profiling of primary metabolites was performed using 
GC-TOF-MS (gas chromatography–time of flight–mass spectrometry). This analysis detected 159 metabolites 
and was run for the three aforementioned groups at 2 time points (t = 0 and t = 3 h), each with 3 replicates. 
Detailed methodology is described in the supplementary methods.
Histological and ultrastructural assessment. Light microscopy. Liver biopsies were fixed in 10% buff-
ered formalin and transferred to 70% ethyl alcohol for further histological processing. Paraffin-embedded sam-
ples were sectioned and stained with hematoxylin and eosin (H&E). The grade of both micro- and macrovesicular 
steatosis was determined by light microscopic assessment of H&E slides grade 0, 0%; grade 1, < 10%; grade 2; 
10–33%; grade 3, 33–66% and grade 4, > 66%.
Transmission electron microscopy (TEM).  Multiple ~1 mm3 liver sections were fixed in EM grade, 2.5% glut-
araldehyde, 2.5% formaldehyde and 0.1 M sodium cacodylate buffer (pH = 7.2), washed twice in 0.1 M sodium 
cacodylate buffer and fixed with 1.0% osmium tetroxide. Fixed samples were alcohol dehydrated with propylene 
oxide and embedded in Epon. Sixty-nanometer sections were cut using a diamond knife ultramicrotome (LKB 
Ultramicrotome, Bromma, Sweden) and viewed and imaged with a Philips 410 transmission electron micro-
scope (Philips Electronics, Eindhoven, the Netherlands). Transmission electron microscopy was performed at the 
Northeastern University Center for Electron Microscopy15.
Mitochondrial scoring was adapted from Ben Mosbah et al.16. Mitochondria in a minimum of 20 hepatocytes 
from a minimum of 3 sections per liver were scored as follows: 0, normal mitochondria; score 1, prominent cris-
tae; score 2, swelling; presence of electron-dense amorphous material.
Statistical analysis and data processing. Statistical analysis was performed in GraphPad Prism 
(GraphPad Software, San Diego, CA). Differences in cofactor and metabolite levels between pre- and 
post-perfusion were analyzed by Wilcoxon-signed rank test or paired student’s t-test following normality testing 
(Kolmogorov-Smirnov test), or repeated measures analysis of variance (ANOVA) when comparing 3 time points. 
Statistical analysis of normally distributed data sets was performed with an unpaired student’s t-test. Data are 
expressed as median ± interquartile range, unless otherwise specified.
Methods for principal component analysis and heat map construction are provided in the supplementary 
methods.
Results
Liver function and hepatocellular injury during SNMP. As an initial assessment, various aspects of 
hepatic function were evaluated during SNMP of discarded DCD and DBD livers (n = 21). A sustained produc-
tion of bile was observed during SNMP, ranging from 0.45–18.2 mL • kg−1 liver/3 hours (Fig. 2A). Oxygen uptake, 
estimated from the difference between in- and outflow oxygen content, increased from 1.19 to 5.15 mL O2 • min−1 
• kg−1 liver in the first 2 hours (P < 0.001), after which it plateaued (Fig. 2B).
To assess hepatocellular uptake and clearance function, ICG was administered after 3 hours of perfusion 
and clearance from the perfusate was monitored for an additional 30 minutes. A perfusate clearance rate of 
15.0 ± 2.4% • min−1 (95% CI) was observed (Fig. 2C), just below the normal range of plasma disappearance 
rate (16–25% • min−1)17. SNMP did not induce hepatocellular injury, as no increase in alanine aminotransferase 
(ALT) was observed after the initial washout phase (Fig. 2D).
Cofactor and energy status in the liver during subnormothermic machine perfusion. Metabolic 
cofactors were measured in the aforementioned 3 groups (n = 9 discarded livers) and in intraoperative con-
trol samples (n = 12 liver biopsies). A significant increase in ATP content was observed after 3 hours of SNMP 
(4.12-fold, P = 0.004) (Fig. 3A), as well as a not statistically significant increase in the ratio of ATP to ADP 
(2.9-fold, P = 0.07) and energy charge (defined as: (ATP + 1/2ADP)/(ATP + ADP + AMP)) (1.93-fold, P = 0.12), 
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which did not reach significance (Fig. S1A/B). Compared to biopsies taken from fresh livers, the ATP:ADP ratio 
as well as the energy charge decreased slightly, yet this did not reach statistical significance (P < 0.1).
The ratio of flavin and nicotinamide is the result of NAD+/FAD reduction pathways and oxidation by the 
electron transport chain, driving oxidative phosphorylation. The ratio NADH:NAD+ was not significantly altered 
by perfusion, and both pre- and postperfusion measurements were not significantly different from fresh sam-
ples (Fig. 3B). The reduced form of FAD (FADH2) was not detectable by this method, but flavin cofactor ratios 
could be approximated by the change in FAD:(FAD + NADH), which were similarly unchanged during perfusion 
(P > 0.05; Fig. 3C). Fresh values of FAD:(FAD + NADH) were significantly lower than both pre- and postper-
fusion levels (P ≤ 0.03). Relative to fresh liver samples, a significant decrease in NADPH:NADP + was observed 
preperfusion, which returned to fresh levels after SNMP (Fig. 3D; 3.48-fold, P = 0.004).
Metabolomic changes in the liver during subnormothermic machine perfusion. An untargeted 
metabolomics analysis was performed on machine perfused hepatic tissue of the three aforementioned groups 
to determine levels of metabolites relevant to ischemia and energy metabolism. The relative concentrations 
of 159 annotated primary metabolites were determined. Table 1 summarizes all near-significantly (P < 0.10) 
changed metabolites during perfusion (t0–t3), stratified according to metabolite class and associated pathways 
derived from the Human Metabolome Database (HMDB)18 and the Kyoto Encyclopedia of Genes and Genomes 
(KEGG)19. Remarkable statistically significant (P < 0.05), or nearing significant (0.10 ≥ P ≥ 0.05) changes 
amongst primary metabolites are seen in sugar compounds, amino acids and derivatives, as well as carboxylic-/
keto- and hydroxyl acids (Table 1). Glucose-6-posphate and fructose-6-phosphate were significantly decreased 
(P < 0.05), while 3-phosphoglycerate did not increase significantly (P = 0.10) (Fig. 4A). In the first hour of SNMP, 
accumulated tissue lactic acid is released into the perfusate as lactate. After the first hour, a decrease in both tissue 
and perfusate lactate content was found, reflecting oxidation back to pyruvate (P = 0.008) (Fig. 4B). Alterations 
Figure 2. Characterization of function and injury. (A) Cumulative production of bile. Bile flow was measured 
hourly and was sustained for 3 hours of SNMP (n = 21, mean ± sem) (B) Oxygen uptake from the perfusate. 
The oxygen uptake rate calculated from in- and outflow partial oxygen (pO2) increased substantially during 
the first two hours of SNMP preservation (n = 21, mean ± sem (shaded)) (C) Clearance of indocyanine 
green (ICG). The postperfusion clearance of ICG was reduced from reference values (blue shaded) under ex 
vivo subnormothermic conditions (n = 7, mean ± sem (shaded)). (D) Release of alanine aminotransferase. 
Significant ALT release was observed in the first 30 minutes, after which release of ALT was reduced to a 
minimum for the remainder of the SNMP (n = 21).
www.nature.com/scientificreports/
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were found in TCA cycle intermediates that were most proximal to pyruvate, with significant increases in citrate 
(4.95-fold; P < 0.05) and α -ketoglutarate (3.86-fold; P < 0.01) (Fig. 4C). Differences in TCA metabolite levels 
between the t0 and t3 time points tapered for the metabolites more downstream in the TCA cycle (i.e., from 
succinate onward).
Metabolomic phenotypes of severely ischemic and steatotic injury during SNMP. In a subse-
quent analysis, liver groups with differing degrees of injury and parenchymal hepatopathology were compared. 
As a control group, DCD livers with a WIT of < 30 min were used (DCD < 30 min group). DCD livers with a long 
WIT of > 30 min and steatotic livers (macrosteatosis > 33%; WIT of < 30 min) were used as severe injury groups 
(DCD > 30 min group and Steatotic DCD group).
Compared to the DCD < 30 min group, more extensive injury was observed in the severe injury livers, as 
evidenced by the increased alanine aminotransferase (ALT) (P = 0.03), potassium (P = 0.01), and lactate levels 
(steatotic DCD livers only; P = 0.0002) in the perfusate (Fig. 5). Common effects of SNMP notwithstanding, we 
anticipated that livers with varying degrees of warm ischemic and steatotic injury would reveal distinguishing 
metabolomic profiles. A heat map representation in Fig. 6 shows relative concentrations of primary metabo-
lites before and after perfusion. Nonsteatotic livers showed a clear change with increasing warm ischemia time, 
both before and after perfusion (Fig. 6A). Similarly, steatotic DCD livers could be discriminated from the DCD 
< 30 min group based on their metabolic profile (Fig. 6B). Metabolites that showed a significant or near-significant 
correlation between WIT and steatosis before and after SNMP are listed in Table S2.
Figure 3. Analysis of adenosine and redox cofactors in human liver tissue. (A) ATP concentration in 
biopsies from SNMP- preserved liver grafts. Absolute ATP content increased significantly during SNMP 
preservation (n = 9, P = 0.03) (B) NADH:NAD ratios in human liver biopsies before (n = 9) and after (n = 9) 
SNMP compared to fresh samples (n = 12). The ratio NADH:NAD was unchanged during SNMP (n = 9) and 
did not significantly differ from fresh samples (n = 12) at either time point (P ≥ 0.05) (C) Estimated FAD were 
increased after ischemia, relative to fresh samples (P = 0.03) and remained unchanged during perfusion (n = 9, 
P ≥ 0.05) (D) NADPH:NADP ratios increased significantly during SNMP (n = 9), and were restored to fresh 
liver levels (n = 12; P = 0.0012). Bars represent mean ± sem.
www.nature.com/scientificreports/
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Principal component analysis of the 159 primary metabolites was performed and included the pre- and post-
perfusion profile, which showed clustering of DCD < 30 min group (Fig. 7). Remarkably, one liver in both the 
steatotic DCD and the DCD > 30 min group was identified that appeared to more closely resemble the DCD 
< 30 min group in the PCA. Interestingly, these livers were the least steatotic (macrosteatosis score 2) and had the 
shortest duration of warm ischemia (36 min).
Biological rationale for impaired ATP recovery. The reconstitution of ATP in the DCD > 30 min group 
and steatotic DCD groups differed substantially from the controls (P < 0.02; Fig. 8A), reflecting compromised 
energy recovery during SNMP in these groups. Despite the poor recovery of ATP in the DCD > 30 min group, 
oxygen uptake was comparable to the DCD < 30 min group (Fig. 8B). Compared to the DCD < 30 min, oxidation 
of glutathione (as fold change in GSSG:GSH) was found to be increased substantially in DCD > 30 min livers 










P value Superclass Class Pathways
t0 t3
Mean ± SD Mean ± SD
glycerol 34.37 ± 20.30 14.1 ± 4.08 0.010 0.086 Carbohydrates Sugar alcohols
xylitol 2.62 ± 2.42 0.37 ± 0.20 0.013 0.099
ribulose-5-phosphate 0.31 ± 0.19 0.16 ± 0.08 0.046 0.233 Sugars (mono-, di-, tri) Pentose Phosphate Pathway
N-acetylmannosamine 1.58 ± 0.84 0.60 ± 0.29 0.005 0.072 Sugar catabolism
maltose 68.96 ± 38.26 23.90 ± 16.89 0.005 0.072 Sugar catabolism
lactobionic acid 256.33 ± 171.19 126.1 ± 83.23 0.057 0.264
hexose-6-phosphate 0.20 ± 0.14 0.11 ± 0.06 0.090 0.327
glycerol-alpha-phosphate 108.7 ± 47.67 69.76 ± 35.40 0.067 0.280
glucose-6-phosphate 0.58 ± 0.61 0.09 ± 0.04 0.029 0.161 Gluconeogenesis, Pentose Phosphate Pathway
fructose-6-phosphate 0.38 ± 0.28 0.13 ± 0.03 0.015 0.109 Gluconeogenesis, Pentosie Phophate Pathway
raffinose 46.51 ± 24.07 24.26 ± 16.38 0.036 0.188 Sugar catabolism
glyceric acid 0.45 ± 0.11 1.83 ± 1.55 0.017 0.116 Sugar Acids
valine 23.1 ± 6.62 40.9 ± 9.02 0.0002 0.012 Amino acids and peptides Amino Acids and Derivatives
Amino acid degredation, ammonia 
recycling
threonine 8.05 ± 3.58 16.5 ± 5.33 0.001 0.032
serine 12.2 ± 5.08 22.5 ± 7.57 0.004 0.072
proline 25.8 ± 9.67 42.95 ± 14.14 0.008 0.086 Amino acid degredation
N-acetylglutamate 0.27 ± 0.11 0.35 ± 0.28 0.074 0.294
leucine 27.5 ± 4.62 48.93 ± 12.47 0.0002 0.012 Amino acid degredation
isoleucine 12.2 ± 3.74 28.0 ± 8.75 0.0001 0.012 Amino acid degredation
glutamine 12.2 ± 6.13 27.90 ± 17.88 0.024 0.158 Amino acid degredation, ammonia recycling, urea cycle
succinic acid 1.06 ± 0.86 2.15 ± 1.31 0.053 0.259 Organic acids and derivatives
Carboxylic Acids and 
Derivatives TCA cycle
citric acid 0.81 ± 0.42 3.99 ± 3.24 0.010 0.086 TCA cycle
fumaric acid 9.05 ± 2.58 11.7 ± 3.48 0.088 0.327 TCA cycle, Urea cycle, amino acid degradation
alpha-ketoglutarate 0.09 ± 0.02 0.33 ± 0.24 0.008 0.086 Keto-Acids and Derivatives TCA cycle, ammonia Recycling
lactic acid 131.5 ± 52.72 51.93 ± 27.61 0.001 0.032 Hydroxy Acids and Derivatives Gluconeogenesis, Pyruvate metabolism
2-hydroxyglutaric acid 0.13 ± 0.03 0.21 ± 0.10 0.030 0.161
UDP GlcNAc* 0.21 ± 0.11 0.13 ± 0.07 0.074 0.294 Nucleosides, Pyrimidine Nucleotides
guanosine 0.25 ± 0.09 0.50 ± 0.34 0.054 0.259 nucleotides, and analogues Purine Nucleosides and Analogues
urea 16.47 ± 13.34 34.1 ± 9.80 0.006 0.072 Miscelleneous Ureas Urea cycle, amino acid degredation
uric acid 2.43 ± 1.62 1.04 ± 0.60 0.028 0.161 Imidazopyrimidines
phenylethylamine 0.54 ± 0.68 1.59 ± 1.50 0.077 0.298 Phenethylamines
oxoproline 68.34 ± 32.34 119.8 ± 41.69 0.010 0.086 Pyrrolidines Glutathione metabolism
N-acetyl-D-hexosamine 0.88 ± 0.41 0.35 ± 0.28 0.005 0.072 Unclassified
lactamide 0.22 ± 0.12 0.14 ± 0.03 0.066 0.280 Unclassified
Table 1.  Metabolite changes during SNMP. *Uridine diphosphate-N-acetylglucosamine.
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Steatotic DCD livers showed significantly lower oxygen uptake than both DCD < 30 min and DCD > 30 min 
(P < 0.03; Fig. 8B). Oxidation of both glutathione and NADP+ was less in steatotic livers than in DCD > 30 min 
(Figs 8C and S1C), while the ratio NADH:NAD+ increased significantly more in the steatotic group (P = 0.046; 
Fig. 8D). Steatotic DCD livers appeared to be more resistant to arterial flow, with a higher resistance at the end of 
perfusion (P = 0.04), although flow rates were not significantly affected (Fig. 8E).
Transmission electron microscopy (TEM) revealed marked differences in mitochondrial ultrastructure 
between livers both before (not shown) and after perfusion, with significantly more injury in the DCD > 30 min 
group (P < 0.0001) and to a lesser extent in steatotic DCD livers (P = 0.01; Fig. 8F (top) and G), which concurred 
with poor ATP recovery in these groups (Fig. 8A). After SNMP, mitochondria showed minimal swelling and 
retained discernable inner and outer membranes and cristae in the DCD < 30 min group. Mitochondria of DCD 
> 30 min livers were enlarged and electron-lucent, consistent with mitochondrial swelling as a result of increased 
membrane permeability. Steatotic DCD liver mitochondria showed a more heterogeneous appearance. While 
the majority of the mitochondria had a normal appearance, focal condensation was observed, characterized by 
increased mitochondrial electron density and dilation between the cristae. Representative H&E-stained histology 
sections are shown in Fig. 8F (bottom).
Discussion
Nearly 40% of liver transplant candidates wait over 2 years for a liver transplant, while 10–15% of patients dies as 
a direct result of the insufficient supply of transplantable donor livers20,21. To increase this supply, the transplanta-
tion of DCD livers has increased substantially over the last 15 years, but appears to have plateaued at around 6% of 
transplanted livers22. Concerns for inferior long-term outcomes and biliary complications lead to a high discard 
rate of nearly 1 in 3 DCD livers22.
In recent years, ex vivo machine perfusion has shown convincing potential in increasing the viability of human 
livers and improving post-transplant outcome7,23. It was hypothesized that, by restoring oxygenation and provid-
ing metabolic substrates, machine perfusion allows for correction of metabolic perturbations inflicted during 
ischemia24. The understanding of these metabolic changes was mostly superficial, limiting not only the optimiza-
tion of current ex vivo machine perfusion protocols, but importantly, also limiting the pretransplant assessment 
of hepatic function. Here, we present a comprehensive characterization of the ex vivo hepatic metabolic condition 
to provide insight into the processes that may contribute to recovery during SNMP. Moreover, by studying livers 
subjected to varying degrees of warm ischemic and steatotic injury, we aimed to improve the understanding of 
these injurious conditions and their ex vivo recovery.
Figure 4. Metabolite changes of key metabolic pathways. (A) Relative values of detected glycolytic 
intermediates; Glu-6-P, glucose-6-phosphate, Fru-6-P, fructose-6-phosphate; 3-PG, 3-phospoglycerate. Glu-6-P 
and Fru-6-P decreased significantly during perfusion (P = 0.03, P = 0.015, respectively), while 3-PG showed an 
insignificant increase (P = 0.09) (B) Relative values of lactic acid in tissue and perfusate concentration of lactate. 
A large release of lactate was observed in the first hour, after which both tissue lactic acid and perfusate lactate 
levels decreased significantly (P = 0.004). (C) Relative values of intermediates of the TCA cycle. Significant 
increases are observed in levels of citrate, α -ketoglutarate and succinate (P < 0.05). Changes in these metabolic 
pathways represent a reversal of ischemic metabolic shifts and suggest an increase in TCA cycle activity. Bars 
represent mean ± sem.
www.nature.com/scientificreports/
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The SNMP protocol employed here is based on the hypothesis that a controlled pretransplant period of SNMP 
supports hepatic function and allows for metabolic recovery of the liver prior to implantation. Moreover, we pro-
pose that metabolic recovery of the liver in the absence of leukocytes reduces reoxygenation-mediated injury, as 
evidenced by the mild degree of injury sustained during SNMP.
There is growing evidence showing that hepatic ATP content before transplantation and recovery of the 
energy status during reperfusion is positively correlated with favorable posttransplant outcome4,25,26. In clini-
cal studies, a correlation between postpreservation27 or postreperfusion28–30 ATP levels and primary liver graft 
function was suggested. The metabolomic comparison between the ischemic and the perfused liver in this study 
shows a considerable recovery of energy metabolism during SNMP. Most notable were an increase in ATP and 
other adenine nucleotide ratios (such as energy status, which have been suggested to better represent energy 
status31). Additionally, NADPH:NADP+ ratios surpassed fresh levels after perfusion. NADPH increase is likely to 
result from the pentose phosphate pathway activity, supported by reduced Glu-6-P, in an attempt to fuel anabolic 
processes. Moreover, a redox shift towards NADPH would allow for improved oxygen radical scavenging capacity 
through an increased potential to reduce glutathione. Untargeted metabolomic analysis of the liver during perfu-
sion most notably revealed a decrease in carbohydrate metabolites and an increase in amino acids and peptides. 
The observed increase in TCA cycle intermediates likely results from multiple anaplerotic reactions, including 
lactate-pyruvate conversion, but feasibly also from the catabolism of amino acids from the perfusion solution.
ATP depletion during normothermic ischemia results in a compensatory accelerated glycolysis and 
lactate accumulation32. The result on glycolytic intermediates is an increase in glucose-6-phosphate, 
fructose-6-phosphate, and a decrease in intermediates downstream of fructose-2,6-biphosphate33. When oxy-
genation is restored, a reversal is expected as observed here during SNMP. Urea production, which increased 
during SNMP, attests to an active amino acid catabolism during perfusion. Levels of amino acid were main-
tained and even increased, speculatively by a continuous supply in the perfusion media. The significance of an 
Figure 5. Injury markers between control DCD, steatotic, severely warm ischemic livers. (A) Levels of 
alanine transaminase (ALT), (B) potassium, and (C) lactate in the perfusate throughout 3 hours of SNMP. 
Dashed lines reflect normal blood reference values for potassium. Data shown as mean ± sem.
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increased TCA intermediate pool can be functionally explained by the increased demand for electron transport 
chain (ETC) substrates following ischemia34.
During SNMP we observed a high variation in bile production between the 21 perfused livers. Moreover, 
severely ischemic and steatotic DCD groups had a significantly higher release of injury markers. This supported 
our hypothesis that metabolic assessment could discriminate different degrees of liver injury. Numerous clinical 
studies have shown an increased risk of graft failure in DCD livers1,35, with increasing WIT as an additional risk 
factor36. Similarly, macrovesicular steatosis of > 30% is associated with a 60% higher risk of graft loss in the first 
posttransplant year37. In both cases, increased I/R injury is implicated, but different mechanisms are assumed to 
be responsible38. Under normal conditions most of the consumed oxygen is used for ATP production39, while 
only minimal amounts of consumed oxygen result in the production of O2.− and derivative reactive transients 
and subsequent oxidative injury, which is reflected in the redox state of glutathione40. Healthy livers exhibit a high 
reconstitution of ATP and low electron leakage from the ETC, but in the case of prolonged ischemia mitochon-
drial dysfunction results in poor ATP production and increased formation of O2.− during reperfusion41,42.
Figure 6. Metabolomic profile of ischemic and steatotic injury. (A) Heatmap visualization of untargeted 
metabolomic assessment of preperfusion and postperfusion liver grafts. DCD livers with a WIT < 30 min 
(DCD < 30 min) are compared to DCD livers with severe warm ischemia (DCD > 30 min). The heatmap on 
the left shows the profile preperfusion and the right shows the profile postperfusion. (B) DCD < 30 min livers 
are compared to steatotic DCD livers (right). From left to right, the macrosteatosis scores are 0, 0, 0, 2, 3, 3. The 
heatmap on the left shows the profile preperfusion and the right shows the profile postperfusion. Individual 
livers are arranged in columns with increasing warm ischemia from left to right, metabolites are ordered by 
slope correlating relative metabolite levels to ischemia or steatosis. The color gradient used to color the entries 
ranges from green to red, corresponding to relatively low and high abundance of the metabolite respectively. 
Both DCD > 30 min and steatotic DCD livers could be discriminated from DCD < 30 min livers based on their 
visual metabolomic pattern.
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Building on this, the combination of perfusion parameters, metabolomics, and cofactor data gives us an indi-
cation of various mechanisms of injury and recovery and differences between groups. However, it should be noted 
that some of the data pertaining to energy metabolism are incongruent and currently difficult to fully consolidate 
mechanistically. Nonetheless, several hypotheses are supported. Livers subjected to < 30 min WIT exhibited a 
similar oxygen extraction rate and fold increase in the NADH:NAD+ ratio compared with livers subjected to 
> 30 min WIT, yet had higher hepatocellular ATP content than the livers with longer ischemia times. One could 
argue that the difference in ATP levels is attributable to the more abundant conversion of intracellular oxygen 
to superoxide (O2.−), as reflected in the increased GSSG:GSH ratio in the > 30 min WIT group, which would 
reduce the available oxygen to act as terminal substrate for the ETC (at complex IV). After all, the magnitude of 
the GSSG:GSH ratio increase is approximately equal to the magnitude of the ATP decrease. This phenomenon 
does not have to affect the extent to which NADH is oxidized as long as the liberated electron can leave the ETC 
and react with oxygen, either leaking pre-complex IV (forming O2.−) or reacting with oxygen via complex IV 
(forming water). However, the notable mitochondrial structural aberrations in the > 30 min WIT group com-
pared to the relatively unaffected mitochondria in the WIT < 30 min group strongly suggest that mitochondria 
are afflicted, which would most likely translate to perturbations in ETC function and the NADH:NAD+ ratio, 
favoring the accumulation of NADH. The observation that these ratios do not exhibit intergroup differences is 
therefore elusive. Moreover, the TCA cycle intermediates exhibit concentration differences between t0 and t3 
with respect to the early intermediates (citrate and α -ketoglutarate), but these differences level out at the more 
downstream metabolites (succinate, fumarate, and malate). This tapered trend suggests that the catalytic rates, 
substrate affinities, or functionality of the enzymes that regulate the TCA cycle changed during SNMP, shifting 
the rate-limiting step from oxalosuccinate (before α -ketoglutarate) to succinyl-CoA or succinate. The exact cause 
for this process is unclear.
Interestingly, we found convincing indications of a distinctive mechanism at play in steatotic livers, which 
similarly demonstrated a poor recovery of ATP – while oxidative stress appeared more mitigated. Steatotic livers 
exhibit a compound sensitivity to I/R injury, perhaps secondary to a preexistent dysfunctional mitochondrial res-
piration43. Lipid accumulation increases hepatocyte size substantially and can decrease sinusoidal space by 50%44. 
The mechanical compression causes perturbed microcirculatory function that in turn results in compromised 
flow45. It has further been speculated that increased diffusional distances, in enlarged hepatocytes result in poor 
oxygen delivery46. We observed an increased arterial resistance in steatotic human livers during SNMP, however, 
flow was not sufficiently compromised to account for reduced oxygen consumption found in these grafts, sug-
gesting a role of poor delivery of oxygen to the mitochondria. We show here that ex vivo machine perfusion can 
identify differences in mitochondrial respiration and recovery of energy stores between different groups of livers 
pretransplantation.
This study is limited by the lack of clinical transplantation or ex vivo simulated (pseudo-) reperfusion with 
whole blood to correlate our findings to a posttransplant or postreperfusion outcome. Nevertheless, the criteria 
with which livers were selected for metabolomic analysis allow cross-reference to posttransplant outcomes in 
large cohort studies. For instance, data from the United States Organ Procurement and Transplantation Network 
revealed that warm ischemic time (defined as in this study) in excess of 30 minutes increased the risk of graft loss 
by 77%, compared to low ischemic times (< 15 min)36. Furthermore, owing to the heterogeneity of discarded 
livers, results in perfusion parameters (bile flow, oxygen uptake) and energy metabolism were highly variable 
Figure 7. Multivariate analysis of pre- and postperfusion metabolomic profile. Principal component 
analysis of DCD < 30 min (green), DCD > 30 min (black), and steatotic DCD livers (grey) pre- (open circles) 
and postperfusion (filled circles), providing a 2-dimensional (PC1/PC2) representation of the untargeted 
metabolomic profile. Clustering of control livers is seen, both pre- and postperfusion. All but one of the 
steatotic DCD and DCD > 30 min livers show separation from the DCD < 30 min livers, lying outside the 95% 
confidence interval of the pre- and postperfusion controls (black ellipses).
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Figure 8. Mitochondrial respiratory function and ATP recovery. (A) Absolute ATP content at the end of 
perfusion in the different groups (n = 3). Final ATP levels were significantly lower in the DCD > 30 min and 
steatotic DCD groups (P < 0.02). (B) Oxygen uptake rates between groups throughout perfusion and total 
oxygen consumption, determined by the area under the curve. Total oxygen uptake was significantly lower in 
steatotic DCD livers, compared to the non-steatotic livers (DCD > 30 min and DCD < 30 min) (P < 0.03). (C) 
Change in ratio of oxidized to reduced glutathione (GSSG:GSH) during perfusion (t3/t0) in the different groups 
as an indicator of oxidative stress. DCD > 30 min livers exhibited the largest increase in GSSG:GSH, with a 
significantly higher ratio change than the DCD < 30 min group (P = 0.007). (D) Change in ratio of NADH to 
NAD+ during perfusion in different groups. DCD < 30 min and DCD > 30 min groups show minimal change 
in NADH:NAD, while steatotic DCD livers exhibit a significant increase (P = 0.046). (E) Arterial resistance at 
the end of perfusion and flow through the portal vein (PV) and hepatic artery (HA). Arterial resistance was 
significantly higher in the steatotic DCD livers (P < 0.05), but the difference in flow through the arterial or 
portal system did not reach statistical significance (shown as mean ± sem). (F) Structural and ultrastructural 
preservation. Transmission electron microscopy images of representative DCD < 30 min, DCD > 30 min, 
and steatotic DCD livers (top). Corresponding H&E photomicrographs are shown in the bottom row. m, 
mitochondria; Nucl, nucleus; lipid; intracellular lipid droplet. (G) Mitochondrial injury scoring. Injury is 
scored based on the appearance of cristae, swelling and intramitochondrial deposition of amorphous material. 
Mitochondrial injury was increased in both DCD > 30 min livers and steatotic DCD livers compared to DCD 
< 30 min livers (n = 2 × 20 cells, mean ± sem) (P < 0.01).
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between organs. Some of these parameters appeared in other work to be dependent on the donor characteristics 
used to identify subgroups here6. To avoid substantial heterogeneity in the subgroup analysis, metabolomic anal-
ysis and comparison between groups was limited to livers that met select inclusion criteria. As a result, a smaller 
number of livers could be included.
Although metabolomic analysis has seen considerable application in the study of hepatobiliary disease, it’s 
application in human liver transplantation remains relatively underexplored. In a recent study, the metabolome of 
pretransplant tissue biopsies was able to separate livers resulting in early allograft dysfunction, identifying poten-
tial 93 biomarkers associated with poor posttransplant function11. SNMP may improve on this cross-sectional 
metabolomics, allowing a dynamic evaluation of hepatic function. Dynamic metabolomic analyses have been per-
formed to elucidate early posttransplant metabolic changes in both bile samples13 and sequential liver biopsies12. 
The clinical application of metabolomics would require rapid assessment of the donor liver to satisfy the 
time-constrained logistics of transplantation. In the near future, emerging techniques, such as rapid evapora-
tive ionization mass spectrometry, which has shown use for in situ applications47, will enable near–real-time 
metabolomic profiling. This could help to distinguish organs that are transplantable from those that should be 
discarded. To identify definitive biomarkers during ex vivo assessment of the liver prospective testing is required 
with correlation to clinical outcome parameters, as these become available in the translation of machine perfusion 
to clinical application.
In conclusion, this comprehensive assessment of the liver during subnormothermic machine perfusion has 
revealed various metabolic changes that occur during functional preservation. Improvement of energetic cofac-
tors and redox shifts during machine perfusion are likely to contribute to improved function after reperfusion. 
Untargeted metabolomic profiling was able to cluster livers with similar metabolic patterns based on the degrees 
of injury, including steatosis and severe warm ischemia in DCD livers. Moreover, perfusion parameters combined 
with differences in metabolic factors between steatotic and severely warm ischemic DCD livers suggested variable 
mechanisms that result in poor recovery of ATP in these livers. These results show great promise for the use of 
metabolomic analysis during machine perfusion of the liver. As new machine perfusion strategies are translated 
into clinical application, a tandem application with metabolomic assessment is warranted.
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